Clicky

Eliem Therapeutics, Inc(ELYM)

Description: Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems in the United States. The company's lead clinical-stage candidates include ETX-810, a novel palmitoylethanolamide prodrug that is in Phase IIa clinical trials for the treatment of diabetic peripheral neuropathic pain and pain associated with lumbosacral radiculopathy; and ETX-155 is a neurosteroid GABAA receptor positive allosteric modulator for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures. Its lead preclinical program includes Kv7.2/3 potassium channel opener for epilepsy and pain; and novel analog of 2,3- benzodiazepine for the treatment of generalized anxiety disorder. The company was incorporated in 2018 and is headquartered in Redmond, Washington.


Keywords: Biotechnology Pain Neuroscience Disorders Chronic Pain Epilepsy Gabaa Receptor Positive Allosteric Modulators Major Depressive Disorder Neuropathic Pain Peripheral Neuropathy Neurophysiology Anxiety Disorder Treatment Of Major Depressive Disorder Palmitoylethanolamide Treatment Of Generalized Anxiety Disorder Perimenopausal Depression

Home Page: www.eliemtx.com

ELYM Technical Analysis

23515 NE Novelty Hill Road
Redmond, WA 98053
United States
Phone: 425 276 2300


Officers

Name Title
Mr. Robert W. Azelby M.B.A. Pres, CEO & Director
Ms. Erin M. Lavelle Exec. VP, COO & CFO
Dr. Valerie Morisset Ph.D. Chief Scientific Officer and Exec. VP of R&D
Mr. James B. Bucher J.D. Exec. VP, Gen. Counsel & Sec.
Ms. Jo Palmer-Phillips Ph.D. Chief Devel. Officer
Dr. Mark Versavel M.B.A., M.D., MBA, Ph.D. Interim Chief Medical Officer
Ms. Susan Franks M.S. Sr. VP & Head of Regulatory Affairs

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.4943
Price-to-Sales TTM: 0
IPO Date: 2021-08-10
Fiscal Year End: December
Full Time Employees: 43
Back to stocks